[go: up one dir, main page]

NO20071702L - Fremgangsmate for fremstilling av 4,5-dihydro-pyrazolo[3,4-C]pyrid-oner - Google Patents

Fremgangsmate for fremstilling av 4,5-dihydro-pyrazolo[3,4-C]pyrid-oner Download PDF

Info

Publication number
NO20071702L
NO20071702L NO20071702A NO20071702A NO20071702L NO 20071702 L NO20071702 L NO 20071702L NO 20071702 A NO20071702 A NO 20071702A NO 20071702 A NO20071702 A NO 20071702A NO 20071702 L NO20071702 L NO 20071702L
Authority
NO
Norway
Prior art keywords
pyrazolo
dihydro
preparation
pyridones
phenylhydrazines
Prior art date
Application number
NO20071702A
Other languages
English (en)
Inventor
Bang-Chi Chen
Boguslaw M Mudryk
Nicolas Cuniere
Lucius Rossano
Huiping Zhang
Rafael Shapiro
Matthew Oberholzer
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20071702L publication Critical patent/NO20071702L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

En ny fremgangsmåte, og mellomprodukter fra denne, for fremstilling av 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-oner med formel (I), fra passende fenylhydraziner, er beskrevet. (I) Disse forbindelsene kan være anvendelige som faktor Xa-hemmere.

Claims (1)

  1. En ny fremgangsmåte, og mellomprodukter fra denne,
    for fremstilling av 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-oner med formel (I), fra passende fenylhydraziner, er beskrevet.
    Disse forbindelsene kan være anvendelige som faktor Xa-hemmere.
NO20071702A 2004-09-28 2007-03-30 Fremgangsmate for fremstilling av 4,5-dihydro-pyrazolo[3,4-C]pyrid-oner NO20071702L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61393804P 2004-09-28 2004-09-28
US68899905P 2005-06-09 2005-06-09
US11/235,510 US7396932B2 (en) 2004-09-28 2005-09-26 Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
PCT/US2005/034548 WO2007001385A2 (en) 2004-09-28 2005-09-27 Process for preparing 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones

Publications (1)

Publication Number Publication Date
NO20071702L true NO20071702L (no) 2007-05-25

Family

ID=36100191

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071702A NO20071702L (no) 2004-09-28 2007-03-30 Fremgangsmate for fremstilling av 4,5-dihydro-pyrazolo[3,4-C]pyrid-oner

Country Status (12)

Country Link
US (1) US7396932B2 (no)
EP (1) EP1805178A2 (no)
JP (1) JP2008514712A (no)
KR (1) KR20070067177A (no)
AR (1) AR051304A1 (no)
AU (1) AU2005333566A1 (no)
BR (1) BRPI0516187A (no)
CA (1) CA2582233A1 (no)
IL (1) IL182177A0 (no)
MX (1) MX2007003702A (no)
NO (1) NO20071702L (no)
WO (1) WO2007001385A2 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TW200303201A (en) * 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
US20070203178A1 (en) * 2004-09-28 2007-08-30 Malley Mary F Crystalline solvates of apixaban
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
SI3246021T1 (sl) 2010-02-25 2020-03-31 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacije apiksabana
ITMI20111135A1 (it) * 2011-06-22 2012-12-23 Dipharma Francis Srl Procedimento per la preparazione di apixaban
ITMI20111047A1 (it) * 2011-06-10 2012-12-11 Dipharma Francis Srl Forma cristallina di apixaban
WO2012168364A1 (en) * 2011-06-10 2012-12-13 Dipharma Francis S.R.L. Apixaban preparation process
EP2554159A1 (en) 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
WO2013119328A1 (en) * 2012-02-07 2013-08-15 Assia Chemical Industries Ltd. Solid state forms of apixaban
US9045473B2 (en) * 2012-03-14 2015-06-02 Dr. Reddy's Laboratories Ltd. Forms of Apixaban
WO2013174498A1 (en) 2012-05-24 2013-11-28 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
WO2014072884A1 (en) 2012-11-12 2014-05-15 Alembic Pharmaceuticals Limited Process for the synthesis of apixaban
CZ304846B6 (cs) * 2012-11-13 2014-12-03 Zentiva, K.S. Způsob přípravy APIXABANU
EP2752414A1 (en) 2013-01-04 2014-07-09 Sandoz AG Crystalline form of apixaban
WO2014108919A2 (en) * 2013-01-09 2014-07-17 Msn Laboratories Limited NOVEL INTERMEDIATE AND POLYMORPHS OF 1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXOPIPERIDIN-1-YL)PHENYL]-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-c] PYRIDINE-3-CARBOXAMIDE AND PROCESS THEREOF
CZ2013305A3 (cs) 2013-04-23 2014-11-05 Zentiva, K.S. Nové krystalické formy APIXABANU a způsob jejich přípravy
US20160113912A1 (en) 2013-06-18 2016-04-28 Cadila Healthcare Limited An improved process for the preparation of apixaban and intermediates thereof
CN103360391B (zh) * 2013-08-06 2015-03-25 齐鲁制药有限公司 阿哌沙班新晶型及其制备方法
CN104370902A (zh) * 2013-08-12 2015-02-25 药源药物化学（上海）有限公司 一种阿哌沙班新晶型及其制备方法
CN103923080B (zh) * 2014-04-04 2016-06-22 苏州景泓生物技术有限公司 一种制备抗血栓药物阿哌沙班的方法
WO2015177801A1 (en) * 2014-05-23 2015-11-26 Symed Labs Limited Novel process for the preparation of a lactam-containing compound
ES2651480T3 (es) * 2014-07-11 2018-01-26 Laboratorios Lesvi S.L. Procedimiento para preparar apixabán
HU231122B1 (hu) 2014-08-06 2020-11-30 Egis Gyógyszergyár Zrt Eljárás apixaban előállítására
WO2016035007A2 (en) 2014-09-05 2016-03-10 Unichem Laboratories Limited An improved process for the preparation of apixaban and intermediates thereof
EP3098221B1 (en) * 2014-10-15 2017-12-06 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for preparing apixaban form n-1
EP3212620B1 (en) * 2014-10-28 2020-11-25 Jubilant Generics Limited (Formerly Jubilant Life Sciences Division) Process for the preparation of apixaban and intermediates thereof
HU230991B1 (hu) 2014-11-19 2019-08-28 Egis Gyógyszergyár Zrt. Eljárás és köztitermék apixaban előállítására
US9603846B2 (en) 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
CN104892601B (zh) * 2015-06-09 2017-09-19 江苏中邦制药有限公司 一种抗血栓药物阿哌沙班的制备方法
EP3064497A1 (en) * 2015-07-20 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Dimer impurities of apixaban and method to remove them
WO2017088841A1 (en) 2015-11-26 2017-06-01 Zentiva, K.S. Preparation of a drug form containing amorphous apixaban
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
KR102188341B1 (ko) 2018-10-24 2020-12-08 하나제약 주식회사 아픽사반의 제조방법
EP3666773A1 (en) 2018-12-11 2020-06-17 KRKA, D.D., Novo Mesto Process for preparing apixaban
JP2022022550A (ja) * 2020-06-26 2022-02-07 ダイト株式会社 アピキサバンの新規製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE67187B1 (en) * 1990-06-15 1996-03-06 Merck & Co Inc A crystallization method to improve crystal structure and size
CZ20011726A3 (cs) * 2000-05-26 2002-02-13 Pfizer Products Inc. Způsob reakční krystalizace, který umoľňuje řídit velikost částic
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
SI1427415T1 (sl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Sestavine, ki vsebujejo laktame in njihovi derivati kot inhibitorji faktorja xa
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
EP1807086A1 (en) 2004-10-25 2007-07-18 Boehringer Ingelheim International GmbH Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
US20060160841A1 (en) 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation

Also Published As

Publication number Publication date
IL182177A0 (en) 2007-07-24
AU2005333566A1 (en) 2007-01-04
US7396932B2 (en) 2008-07-08
WO2007001385A2 (en) 2007-01-04
WO2007001385A3 (en) 2007-05-31
AR051304A1 (es) 2007-01-03
BRPI0516187A (pt) 2008-08-26
EP1805178A2 (en) 2007-07-11
MX2007003702A (es) 2007-04-20
JP2008514712A (ja) 2008-05-08
WO2007001385B1 (en) 2007-07-12
US20060069258A1 (en) 2006-03-30
CA2582233A1 (en) 2007-01-04
KR20070067177A (ko) 2007-06-27

Similar Documents

Publication Publication Date Title
NO20071702L (no) Fremgangsmate for fremstilling av 4,5-dihydro-pyrazolo[3,4-C]pyrid-oner
NO20071707L (no) Fremstilling av 4,5-dihydro-pyrazolo[3,4-C]Pyrid-2-oner
NO20092692L (no) MAPK/ERK kinaseinhibitorer
NO20081133L (no) Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer
NO980154L (no) Sykliske GMP-spesifikke fosfodiesteraseinhibitorer
GB0007371D0 (en) Chemical compounds
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
NO20054852L (no) GFAT inhibitorer
NO330968B1 (no) Ny fremgangsmate for syntesen av (1S)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
NO20071634L (no) Effektiv syntese av 4,5-dihydro-pyrazolo(3,4-C)pyrid-2-oner
WO2006059149A8 (en) Arylsulfonylnaphthalene derivatives as 5ht2a antagonists
DE60322417D1 (en) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
NO20061363L (no) Pyrazolo- og imidazo- pyrimidinderivater
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
PL372409A1 (en) Novel alkoxypyridine-derivatives
MY141020A (en) Novel pparalpha and ppargamma agonists
WO2007062308A3 (en) Homo- and heterocyclic compounds suitable as cetp inhibitors
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
NO20073276L (no) Metode for fremstilling av aminoetoksybenzylalkoholer
NO20055750L (no) Nye kjemiske forbindelser
NO20064012L (no) Kjemisk prosess
SG149005A1 (en) Process for the preparation of thiazolopyrimidines
NO20081103L (no) 9-Aminoklarbonylsubstituerte derivater av glycylcykliner
TW200732334A (en) A 4-oxo-1-(3-substituted phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application